Bionano Genomics (BNGO) EBITDA (2017 - 2026)

Bionano Genomics has disclosed EBITDA across 10 years of filings, most recently posting -$7.2 million for Q2 2026.

• In Q2 2026, EBITDA rose 7.46% year-over-year to -$7.2 million; the TTM figure through Jun 2026 stood at -$32.2 million (up 55.36% YoY), while the FY2025 annual figure was -$33.3 million, up 67.94% from the prior year.
• EBITDA came in at -$7.2 million for Q2 2026 at Bionano Genomics, up from -$7.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$7.2 million in Q2 2026 to a low of -$113.2 million in Q3 2023.
• Average EBITDA over 5 years is -$27.7 million, with a median of -$27.4 million recorded in 2022.
• Year-over-year, EBITDA slumped 252.15% in 2023 and jumped 80.55% in 2025.
• Over 5 years, EBITDA stood at -$37.5 million in 2022, then jumped by 33.51% to -$25.0 million in 2023, then surged by 52.15% to -$11.9 million in 2024, then rose by 28.52% to -$8.5 million in 2025, then increased by 15.44% to -$7.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$7.2 million in Q2 2026, -$7.9 million in Q1 2026, and -$8.5 million in Q4 2025.